Pharming Group Valuation
| PHGUF Stock | USD 0.75 0.07 8.54% |
Pharming Group is overvalued. Pharming Group NV holds a recent Real Value of $0.65 per share. The prevailing price of the company is $0.75. Our model determines the value of Pharming Group NV from analyzing the company fundamentals such as Return On Equity of 0.17, operating margin of 0.18 %, and Shares Outstanding of 652.41 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Pharming Group's price fluctuation is dangerous at this time. Calculation of the real value of Pharming Group NV is based on 3 months time horizon. Increasing Pharming Group's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Pharming pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Pharming Group NV. Since Pharming Group is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pharming Pink Sheet. However, Pharming Group's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.75 | Real 0.65 | Hype 0.75 |
The real value of Pharming Pink Sheet, also known as its intrinsic value, is the underlying worth of Pharming Group NV Company, which is reflected in its stock price. It is based on Pharming Group's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Pharming Group's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Pharming Group NV helps investors to forecast how Pharming pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pharming Group more accurately as focusing exclusively on Pharming Group's fundamentals will not take into account other important factors: Pharming Group Total Value Analysis
Pharming Group NV is at this time anticipated to have takeover price of 721.19 M with market capitalization of 880.76 M, debt of 122.65 M, and cash on hands of 189.96 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Pharming Group fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
721.19 M | 880.76 M | 122.65 M | 189.96 M |
Pharming Group Investor Information
About 16.0% of the company shares are owned by institutional investors. The book value of Pharming Group was at this time reported as 0.3. The company had not issued any dividends in recent years. Pharming Group NV had 1:10 split on the 5th of March 2013. Based on the analysis of Pharming Group's profitability, liquidity, and operating efficiency, Pharming Group NV is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Pharming Group Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pharming Group has an asset utilization ratio of 47.83 percent. This implies that the Company is making $0.48 for each dollar of assets. An increasing asset utilization means that Pharming Group NV is more efficient with each dollar of assets it utilizes for everyday operations.Pharming Group Ownership Allocation
Pharming Group owns a total of 652.41 Million outstanding shares. Roughly 81.6 pct. of Pharming Group outstanding shares are held by general public with 1.97 % owned by insiders and only 16.43 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Pharming Group Profitability Analysis
The company reported the revenue of 167.68 M. Net Income was 16 M with profit before overhead, payroll, taxes, and interest of 177.73 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Pharming Group's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Pharming Group and how it compares across the competition.
About Pharming Group Valuation
The pink sheet valuation mechanism determines Pharming Group's current worth on a weekly basis. Our valuation model uses a comparative analysis of Pharming Group. We calculate exposure to Pharming Group's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pharming Group's related companies.Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Pharming Grp operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 277 people.
8 Steps to conduct Pharming Group's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Pharming Group's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Pharming Group's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Pharming Group's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Pharming Group's revenue streams: Identify Pharming Group's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Pharming Group's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Pharming Group's growth potential: Evaluate Pharming Group's management, business model, and growth potential.
- Determine Pharming Group's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Pharming Group's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Pharming Group Growth Indicators
Investing in growth stocks can be very risky. If the company such as Pharming Group does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 648.7 M | |
| Quarterly Earnings Growth Y O Y | 2.089 | |
| Forward Price Earnings | 151.5152 | |
| Retained Earnings | -269.8 M |
Complementary Tools for Pharming Pink Sheet analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |